Assessment of Platelet-Dependent Thrombosis by an ex Vivo Arterial Injury Model: a Placebo Controlled Trial of Clopidogrel as Antiplatelet Therapy in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease

Trial Profile

Assessment of Platelet-Dependent Thrombosis by an ex Vivo Arterial Injury Model: a Placebo Controlled Trial of Clopidogrel as Antiplatelet Therapy in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Feb 2016

At a glance

  • Drugs Clopidogrel (Primary) ; Aspirin
  • Indications Acute coronary syndromes; Angina pectoris; Coronary artery disease; Thrombosis
  • Focus Pharmacodynamics
  • Acronyms EL CAD
  • Most Recent Events

    • 28 Jan 2016 Accrual to date is 104% according to United Kingdom Clinical Research Network (5159).
    • 24 May 2013 Accrual to date is 97% according to United Kingdom Clinical Research Network (14278).
    • 19 Apr 2013 Accrual to date is 94% according to United Kingdom Clinical Research Network (14278).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top